Rodríguez ML, Pérez PS, Palmero CR, Serra VY

Idioma: Español
Referencias bibliográficas: 45
Paginas: 42-47
Archivo PDF: 85.79 Kb.

RESUMEN

La enfermedad cerebrovascular representa la tercera causa de muerte en los países desarrollados y en vías de desarrollo y sus secuelas se comportan como la primera causa de invalidez en los adultos. La espasticidad, como componente del defecto motor en el enfermo constituye una secuela más, invalidante en ocasiones e imprescindible para lograr la recuperación parcial del enfermo. Se hace una revisión del concepto de espasticidad, las principales características clínicas, comentarios fisiopatológicos y modalidades actuales de tratamiento.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Bonita R. Epidemiology of stroke. Lancet 1992; 339: 342-4.

2. Nitta A, Hayashi K, Hasegawa T, Nabeshima T. Development of plasticity of brain function with repeated trainings and passage of time after basal forebrain lesions in rats. J Neural Transm Gen Seet 1993; 93: 46.

3. Von Steinbuchel N, Poppel E. Domains of rehabilitation: a teorical perspective. Behav Brain Res 1993; 56: 1-10.

4. Young RR. Treatment of spastic paresis. N Engl J Med 1989; 320: 1553-5.

5. Souza RO. Motor hemiplegia and the cerebral organization of movement in man: I. The pyramidal concept: a restatement. Arq Neuropsiquiatr 1989; 47(1): 8-15.

6. Fonseca ST, Holt KG, Saltzman E, Fetters L. A dynamical model of locomotion in spastic hemiplegic cerebral palsy: influence of walking speed. Clin Biomech (Bristol, Avon) 2001; 16(9): 793-805.

7. Meythaler JM. Spastic hypertonia. Appendix. Phys Med Rehabil Clin N Am 2001; 12(4): 953-6.

8. Gracies JM. Pathophysiology of impairment in patients with spasticity and use of stretch as a treatment of spastic hypertonia. Phys Med Rehabil Clin N Am 2001; 12(4): 747-68.

9. Kirkwood A, Dudek SD, Gold JT, Aizenman CD, Bear MF. Common forms of synaptic plasticity in hippocampus and neocortex. Science 1993; 260: 1518-21.

10. Sasaki K, Gemba H. Plasticity of cortical function related to voluntary movement motor learning and compensation following brain dysfunction. Acta Neurochir Suppl (Wien) 1987; 41: 18-28.

11. Katz R. Reevaluation of physiological mechanisms generating the stretch reflex: new hypotheses on the physiopathology of spasticity. Ann Readapt Med Phys 2001; 44(5): 268-72.

12. Hinderer SR, Dixon K. Physiologic and clinical monitoring of spastic hypertonia. Phys Med Rehabil Clin N Am 2001; 12(4): 733-46.

13. Meythaler JM. Concept of spastic hypertonia. Phys Med Rehabil Clin N Am 2001; 12(4): 725-32.

14. Pandyan AD, Price CI, Rodgers H, Barnes MP, Johnson GR. Biomechanical examination of a commonly used measure of spasticity. Clin Biomech (Bristol, Avon) 2001; 16(10): 859-65.

15. Cuadrado ML, Arias JA, Palomar MA, Linares R. La vía piramidal: nuevas trayectorias. Rev Neurol 2001; 32(12): 1151-8.

16. Opara J. Possibilities of subjective and objective evaluation of spasticity. Pol Merkuriusz Lek 2001; 11(61): 109-12.

17. von Koch CS, Park TS, Steinbok P, Smyth M, Peacock WJ. Selective posterior rhizotomy and intrathecal baclofen for the treatment of spasticity. Pediatr Neurosurg 2001; 35(2): 57-65.

18. Burns AS, Meythaler JM. Intrathecal baclofen in tetraplegia of spinal origin: efficacy for upper extremity hypertonia. Spinal Cord 2001; 39(8): 413-9.

19. Gelber DA, Good DC, Dromerick A, Sergay S, Richardson M. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke 2001; 32(8): 1841-6.

20. Leonard CT, Stephens JU, Stroppel SL. Assessing the spastic condition of individuals with upper motoneuron involvement: validity of the myotonometer. Arch Phys Med Rehabil 2001; 82(10): 1416-20.

21. Farmer SE, James M. Contractures in orthopaedic and neurological conditions: a review of causes and treatment. Disabil Rehábil 2001; 23(13): 549-58.

22. Hendricks HT, IJzerman MJ, de Kroon JR, Groen FA, Zilvold G. Functional electrical stimulation by means of the ‘Ness Handmaster Orthosis’ in chronic stroke patients: an exploratory study. Clin Rehabil 2001; 15(2): 217-20.

23. Coré, Carballosa MA, Capote, Díaz R. Study of the tecnics of the neuromuscular facilitation how mean for to diminution of the spasticity in the patients with static encephalic lesions produced by brain-stroke. Med Reabil 2001; (56): 11-16.

24. Harlaar J, Ten Kate JJ, Prevo AJ, Vogelaar TW, Lankhorst GJ. The effect of cooling on muscle co-ordination in spasticity: assessment with the repetitive movement test. Disabil Rehabil 2001; 23(11): 453-61.

25. Bryan J. Rehabilitation. Upwardly mobile. Health Serv J 2001; 111(5754) (Suppl.) 36-7.

26. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Quantifying associated reactions in the paretic arm in stroke and their relationship to spasticity. Clin Rehabil 2001; 15(2): 195-206.

27. Francisco GE, Kothari S, Huls C. GABA agonists and gabapentin for spastic hypertonia. Phys Med Rehabil Clin N Am 2001; 12(4): 875-88.

28. Elovic E. Principles of pharmaceutical management of spastic hypertonia. Phys Med Rehabil Clin N Am 2001; 12(4): 793-816, vii.

29. Barnes MP. Spasticity: a rehabilitation challenge in the elderly. Gerontology 2001; 47(6): 295-9.

30. López S, Isabel, et al. Usefulness of baclofen in spasticity of brain origin. Rev Chil Pediatr 1996; 67(5): 206-11.

31. Garcia LP, et al. Intraspinal blacofen in the treatment of severe spaticity and spasm. Arq Bras Neurocir 1994; 13(4): 163-7.

32. Pagano MA, Ferreiro ME, Herskovits E. Comparative study of tizanidine and baclofen in patients with chronic spasticity. Rev Neurol Argent 1990; 15(1): 27-33.

33. Meythaler JM, Guin-Renfroe S, Johnson A, Brunner RM. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehabil 2001; 82(9): 1155-63.

34. Scott AB, Rosenbaum AL, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973; 12: 924-7.

35. Das TK, Park DM. Botulinum toxin in treating spasticity. Br J Clin Pharmacol 1989; 43: 401-3.

36. Esquenazi A, Mayer N. Botulinum toxin for the management of muscle overactivity and spasticity after stroke. Curr Atheroscler Rep 2001; 3(4): 295-8.

37. Reichel G. Botulinum toxin for treatment of spasticity in adults. J Neurol 2001; 248 (Suppl.) 1: 25-7.

38. Barbero AP, et al. Experience of the treatment with botulinum toxin in spasticity in children. Rev Neurol Clin 2000; 1: 125-30.

39. Hesse S, Brandi-Hesse B, Bardeleben A, Werner C, Funk M. Botulinum toxin a treatment of adult upper and lower limb spasticity. Drugs Aging 2001; 18(4): 255-62.

40. O’Brien CF. Chemodenervation with botulinum toxin for spasticity and dystonia. The effects on gait. Adv Neurol 2001; 87: 265-9.

41. Beck M, Woo A, Leunig M, Ganz R. Gluteus minimus-induced femoral head deformation in dysplasia of the hip. Acta Orthop Scand 2001; 72(1): 13-7.

42. Kim DS, Choi JU, Yang KH, Park CI. Selective posterior rhizotomy in children with cerebral palsy: a 10-year experience. Childs Nerv Syst 2001; 17(9): 556-62.

43. Taira T, Hori T. Selective peripheral neurotomy for spasticity in cerebral palsyl. No Shinkei Geka 2001; 29(12): 1137-50.

44. Lazarett JA, et al. Neurosurgical treatment of spasticity, selective posterior rhizotomy. A new procedure. Bol Med Hosp Infant Méx 1990; 47(2): 72-6.

45. Zafonte RD, Munin MC. Phenol and alcohol blocks for the treatment of spasticity. Phys Med Rehabil Clin N Am 2001; 12(4): 817-32.